S&P 500   4,467.71
DOW   35,123.36
QQQ   367.91
2 Tech Stocks to Buy and One to Avoid in August
His system isolated NVIDIA - Here's His Next Buy. (Ad)
3 Stocks to Buy No Matter Which Way Inflation Moves
3 Stocks to Buy After Heavy Insider Buying
Bizarre Amazon Secret — Not Available on CNN, Fox, or MSNBC (Ad)
2 Alternatives To Tesla (1 Safe, 1 More Risky)
The Rivian Market Is About To Shift Into A Higher Gear 
The single greatest medical breakthrough of all time? (Ad)
7 Best Fintech ETFs to Buy Now
How major US stock indexes fared Wednesday, 8/9/2023
S&P 500   4,467.71
DOW   35,123.36
QQQ   367.91
2 Tech Stocks to Buy and One to Avoid in August
His system isolated NVIDIA - Here's His Next Buy. (Ad)
3 Stocks to Buy No Matter Which Way Inflation Moves
3 Stocks to Buy After Heavy Insider Buying
Bizarre Amazon Secret — Not Available on CNN, Fox, or MSNBC (Ad)
2 Alternatives To Tesla (1 Safe, 1 More Risky)
The Rivian Market Is About To Shift Into A Higher Gear 
The single greatest medical breakthrough of all time? (Ad)
7 Best Fintech ETFs to Buy Now
How major US stock indexes fared Wednesday, 8/9/2023
S&P 500   4,467.71
DOW   35,123.36
QQQ   367.91
2 Tech Stocks to Buy and One to Avoid in August
His system isolated NVIDIA - Here's His Next Buy. (Ad)
3 Stocks to Buy No Matter Which Way Inflation Moves
3 Stocks to Buy After Heavy Insider Buying
Bizarre Amazon Secret — Not Available on CNN, Fox, or MSNBC (Ad)
2 Alternatives To Tesla (1 Safe, 1 More Risky)
The Rivian Market Is About To Shift Into A Higher Gear 
The single greatest medical breakthrough of all time? (Ad)
7 Best Fintech ETFs to Buy Now
How major US stock indexes fared Wednesday, 8/9/2023
S&P 500   4,467.71
DOW   35,123.36
QQQ   367.91
2 Tech Stocks to Buy and One to Avoid in August
His system isolated NVIDIA - Here's His Next Buy. (Ad)
3 Stocks to Buy No Matter Which Way Inflation Moves
3 Stocks to Buy After Heavy Insider Buying
Bizarre Amazon Secret — Not Available on CNN, Fox, or MSNBC (Ad)
2 Alternatives To Tesla (1 Safe, 1 More Risky)
The Rivian Market Is About To Shift Into A Higher Gear 
The single greatest medical breakthrough of all time? (Ad)
7 Best Fintech ETFs to Buy Now
How major US stock indexes fared Wednesday, 8/9/2023
NASDAQ:OCS

Oculis (OCS) Price Target & Analyst Ratings

$13.00
+0.26 (+2.04%)
(As of 08/9/2023 ET)
Compare
Today's Range
$12.69
$13.18
50-Day Range
$11.00
$13.00
52-Week Range
$6.26
$13.95
Volume
18,507 shs
Average Volume
20,756 shs
Market Capitalization
$473.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00

Oculis Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 7 Analyst Ratings

Consensus Analyst Price Target

$33.00
153.85% Upside
High Prediction$64.00
Average Prediction$33.00
Low Prediction$22.00
TypeCurrent
8/10/22 to 8/10/23
1 Month Ago
7/11/22 to 7/11/23
3 Months Ago
5/12/22 to 5/12/23
1 Year Ago
8/10/21 to 8/10/22
Consensus Rating
Buy
Buy
Buy
N/A
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A
Buy
7 Buy rating(s)
7 Buy rating(s)
2 Buy rating(s)
N/A
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
N/A
Consensus Price Target$33.00$25.00$25.00N/A
Predicted Upside153.85% Upside126.81% Upside132.34% UpsideN/A
Get Oculis Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter.


OCS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

OCS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Oculis Stock vs. The Competition

TypeOculisMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.65
2.48
Consensus RatingBuyModerate BuyHold
Predicted Upside153.85% Upside5,099.32% Upside636.80% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/9/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$58.00 ➝ $64.00+402.35%
8/9/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Y. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Target$28.00 ➝ $29.00+127.63%
6/14/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$22.00+91.30%
6/12/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Goodman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
6/12/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
5/10/2023Pareto Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$23.00+115.76%
4/28/2023Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Argyrides
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$27.00+148.62%
(Data available from 8/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












OCS Price Target - Frequently Asked Questions

What is Oculis's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for Oculis stock is Buy based on the current 7 buy ratings for OCS. The average twelve-month price prediction for Oculis is $33.00 with a high price target of $64.00 and a low price target of $22.00. Learn more on OCS's analyst rating history.

Do Wall Street analysts like Oculis more than its competitors?

Analysts like Oculis more than other Medical companies. The consensus rating for Oculis is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how OCS compares to other companies.

Does Oculis's stock price have much upside?

According to analysts, Oculis's stock has a predicted upside of 185.52% based on their 12-month price targets.

What analysts cover Oculis?

Oculis has been rated by Bank of America, HC Wainwright, Robert W. Baird, SVB Leerink, and SVB Securities in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:OCS) was last updated on 8/10/2023 by MarketBeat.com Staff

My Account -